|Home page Health|
An immunotherapy drug that could save some cancer patients from the ordeal of extreme chemotherapy may also help them live longer, researchers say.
Axar.az reports citing BBC.
In a trial, pembrolizumab kept head and neck cancers at bay for an average of two years - five times longer than under chemotherapy.
The patients also suffered far fewer side-effects.
Cases of head and neck cancers are rising in the UK and most are diagnosed late, when they are hard to treat.
2019.11.23 / 21:56